{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        986, 
        1000
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2469, 
        2492
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        887, 
        914
      ]
    }
  ], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        858, 
        863
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        528, 
        557
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        830, 
        856
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1002, 
        1009
      ]
    }
  ], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1014, 
        1015
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        976, 
        985
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "FALSE NEGATIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5", 
      "__extent": [
        880, 
        884
      ]
    }
  ], 
  "Supplementary Report Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1152, 
        1184
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1186, 
        1201
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|Associated Pathologists, LLC d/b/a PathGroup^44D1084007^CLIA|eMARCPlus|TN Cancer Registry|20170919125832||ORU^R01^ORU_R01|201709191258320001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-55-004883^PathSys^44D1084007^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170829131100|||||||20170829000000|&Prostate, Needle Biopsy|1720009335^^^^^^MD^^CMS^D^^^NPI||||||20170830000000|||F||||||C61^Malignant neoplasm of prostate^I10~R97.20^Elevated prostate specific antigen [PSA]^I10|1285672592&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nThe patient's name is \"\" identified by requisition and specimen container label. Received in formalin in a container labeled with the patient's name and \"right anterior medial apex\" are 3 cores of soft tan tissue 10 mm, 10 mm, 14 mm all submitted in cassette 1A. (CMB)\n\n\nPath report.site of origin\n\nRight anterior medial apex\n\n\nPath report.final diagnosis\n\nProstate, right anterior medial apex (MRI guided biopsy):   Prostatic adenocarcinoma, Gleason 3+4=7 (45% pattern 4, grade group 2)   39mm of tumor occupying 95% of the tissue, 3 of 3 cores involved   Tumor present in skeletal muscle.\n\n\nPath report.supplemental reports\n\nAddendum Report: Immunohistochemistry with appropriate controls was performed on block 1A for PTEN and ERG (TMPRSS2:ERG transformation product) in a section containing invasive carcinoma. The results are as follows: ResultsPrognostic Group PTEN intact/No ERG overexpressionFavorable Note: Combined PTEN loss and ERG overexpression has been associated with an increased risk of early biochemical relapse following prostatectomy and higher stage disease. ERG overexpression has been associated with an increased risk of progression on active surveillance References: 1. Reid, AHM, et. al., Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br. J. Cancer. (2010) 102, 678-684. 2. Burg KD, et. al., ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. European Urology (2014) 66(1), 851-860 3. Shah RB. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management. Adv. Anat. Pathol. (2013) 20(2):117-24 4. Nagle RB, et. al., ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate.(2013) 73(11):1233-40 ## End of auxiliary report ##\n\n\nPath report.relevant Hx\n\nHistory - Elevated prostate specific antigen [PSA] (R97.2), PSA 17, history prostate cancer\n\n\n"
}